-Nicholas O Davidson Researcher Activity Profile

Research Author Detailed Information 

Nicholas O Davidson Publication Rate By Year

Nicholas O Davidson has published 2 paper(s) in 2006, 10 paper(s) in 2007, 6 paper(s) in 2008, for a total of 18 research publications in total.

Nicholas O No Davidson Author Information

LAST NAME: davidson

FIRST NAME: Nicholas O

INITIALS: no

AFFILIATION:

Papers

Nicholas O Davidson's Publication Record

1. The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Year Published: 2007
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, College of Medicine, Chicago, Illinois, USA. yyoshida@gh.med.osaka-u.ac.jp
2. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Year Published: 2006
Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63105, USA.
3. Coordinate transcriptional repression of liver fatty acid-binding protein and microsomal triglyceride transfer protein blocks hepatic very low density lipoprotein secretion without hepatosteatosis. Year Published: 2006
Department of Biology, The Heart Institute, San Diego State University, California 92182-4614, USA.
4. Genetic testing in colorectal cancer: who, when, how and why. Year Published: 2007
Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO 63110, USA. nod@wustl.edu
5. Keratinocyte-specific expression of fatty acid transport protein 4 rescues the wrinkle-free phenotype in Slc27a4/Fatp4 mutant mice. Year Published: 2007
Renal Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
6. Disruption of hedgehog signalling in ApoE - /- mice reduces plasma lipid levels, but increases atherosclerosis due to enhanced lipid uptake by macrophages. Year Published: 2007
Department of Pathology, Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, Maastricht, The Netherlands.
7. Deletion of the AU-rich RNA binding protein Apobec-1 reduces intestinal tumor burden in Apc(min) mice. Year Published: 2007
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
8. Conditional intestinal lipotoxicity in Apobec-1-/- Mttp-IKO mice: a survival advantage for mammalian intestinal apolipoprotein B mRNA editing. Year Published: 2007
Department of Medicine, Washington University School of Medicine, 660 South Euclid, St. Louis, MO 63110, USA.
9. Translational approaches to addressing complex genetic pathways in colorectal cancer. Year Published: 2007
Gastroenterology Division, Department of Medicine, Washington University School of Medicine, St. Louis, Mo.
10. Conditional intestinal lipotoxicity in Apobec-1-/- Mttp-IKO mice: a survival advantage for mammalian intestinal apolipoprotein B mRNA editing. Year Published: 2007
Department of Medicine, Washington University School of Medicine, 660 South Euclid, St. Louis, MO 63110, USA.
11. Translational approaches to addressing complex genetic pathways in colorectal cancer. Year Published: 2007
Gastroenterology Division, Department of Medicine, Washington University School of Medicine, St. Louis, Mo 63110, USA.
12. Translational approaches to addressing complex genetic pathways in colorectal cancer. Year Published: 2007
Gastroenterology Division, Department of Medicine, Washington University School of Medicine, St. Louis, Mo 63110, USA.
13. Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation? Year Published: 2008
Dept. of Pathology and Laboratory Medicine, Univ. of Cincinnati, 2120 E. Galbraith Rd., Cincinnati, OH 45237. tsopp@email.uc.edu).
14. Diet-induced obesity and hepatic steatosis in L-Fabp / mice is abrogated with SF, but not PUFA, feeding and attenuated after cholesterol supplementation. Year Published: 2008
Div. of Gastroenterology, Dept. of Medicine, Washington Univ. School of Medicine, St. Louis, MO 63110. nod@wustl.edu).
15. Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation? Year Published: 2008
Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45237, USA.
16. Diet-induced obesity and hepatic steatosis in L-Fabp / mice is abrogated with SF, but not PUFA, feeding and attenuated after cholesterol supplementation. Year Published: 2008
Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
17. Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation? Year Published: 2008
Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45237, USA.
18. Diet-induced obesity and hepatic steatosis in L-Fabp / mice is abrogated with SF, but not PUFA, feeding and attenuated after cholesterol supplementation. Year Published: 2008
Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.